VEXAS Syndrome

1. Disease Information

Overview. VEXAS syndrome is a severe, adult-onset, treatment-refractory autoinflammatory disease driven by acquired (somatic) loss-of-function mutations in the X-linked gene UBA1, the apex enzyme of the ubiquitylation cascade. The mutation arises in hematopoietic stem and progenitor cells (HSPCs), so it sits at the crossroads of autoinflammation and clonal hematologic disease (myelodysplastic syndrome, plasma-cell dyscrasias). The name is an acronym coined in the discovery paper:

Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic — Beck DB et al., NEJM 2020 (PMID:33108101).

It is best understood as a clonal hematopoietic disorder masquerading as, and overlapping with, a host of rheumatologic syndromes (relapsing polychondritis, Sweet syndrome, polyarteritis nodosa, giant cell arteritis, undifferentiated systemic inflammation). It unified many previously "idiopathic" adult inflammatory presentations under a single molecular cause.

Key identifiers. - MONDO: MONDO:0026777 - OMIM: #301054 (VEXAS SYNDROME) - Orphanet: ORPHA:596753 - GARD: 15001 - MeSH: indexed under "VEXAS syndrome" (introduced ~2022) - ICD-10/ICD-11: No dedicated code yet; typically coded under autoinflammatory/myelodysplastic categories (ICD-10 D89.9 / D46.x). ICD-11 has no specific stem code as of this writing — (data gap).

Synonyms / alternative names. "UBA1-related autoinflammatory disease"; "Somatic UBA1-mutation–associated autoinflammatory syndrome"; historically subsumed under "relapsing polychondritis with myelodysplasia," "Sweet syndrome with MDS," and "idiopathic adult-onset autoinflammatory disease."

Data derivation. Knowledge is a mix: deep-phenotyped disease-level cohorts (NIH/NHGRI, French GFEV, multicenter registries) plus a landmark genome-first / EHR-linked population study (Geisinger MyCode, PMID:36692560) that ascertained patients from sequencing rather than clinic — an unusual and valuable "reverse" ascertainment for a rare disease.

Sources: NEJM 2020 (PMID:33108101) · GeneReviews NBK614471 · OMIM 301054

2. Etiology

Primary cause (genetic, somatic). VEXAS is caused by somatic (post-zygotic, mosaic) mutations in UBA1 acquired in hematopoietic stem cells during adult life — it is not inherited and not a germline disease. The canonical mutations hit codon 41 (p.Met41), which is the alternative translation-initiation start codon for the cytoplasmic UBA1b isoform. Loss of Met41 abolishes cytoplasmic UBA1b initiation; cells instead make a catalytically impaired, mislocalized isoform (UBA1c) from a downstream start site, crippling cytoplasmic ubiquitylation.

"We identified 25 men who had somatic mutations in UBA1... The mutations were found in peripheral-blood cells... the somatic mutations affected methionine-41 (p.Met41)." — Beck DB et al., NEJM 2020 (PMID:33108101). (HUMAN_CLINICAL)

Risk factors. - Age: Strongest determinant. Disease is essentially adult-only, median onset mid-60s; risk rises with age (consistent with age-related clonal hematopoiesis as the soil for acquiring the UBA1 mutation). - Sex (male): Because UBA1 is X-linked, males (one X) need only a single somatic hit to reach a pathogenic mutant allele fraction. Males ≈96% of cases. - Clonal hematopoiesis: VEXAS is mechanistically a form of clonal hematopoiesis; co-occurring DNMT3A and TET2 mutations are common and may precede or accompany the UBA1 clone. - Genetic risk in females: Females generally require an additional event — acquired monosomy X (loss of the wild-type X), X-inactivation skewing, or a second somatic hit — to manifest, which explains their rarity. (PMID:33108101; GeneReviews NBK614471).

Protective factors. No established environmental protective factors. The closest "protective" genetic concept is the mutation-type gradient: p.Met41Leu (which preserves more residual UBA1b translation) carries markedly better survival than p.Met41Val. Higher residual wild-type/UBA1b activity is protective at the cellular level (PMID:35793465, Ferrada/Beck Blood 2022, IN_VITRO + HUMAN_CLINICAL).

Gene–environment interactions. No proven exogenous trigger. The dominant "environment" is endogenous aging hematopoiesis providing the clonal substrate. Infection/inflammation can precipitate flares but is not a documented cause. (Largely a data gap for true GxE.)

3. Phenotypes

VEXAS is multisystem. Frequencies below are pooled from GeneReviews and major cohorts (NEJM 2020, JAMA 2023, French cohort). Mark these as HUMAN_CLINICAL.

Constitutional / inflammatory - Recurrent fevers — 65–90%. HPO: HP:0001954 (Recurrent fever) / HP:0011947. Episodic, often weekly; adult onset; recurrent. - Weight loss / cachexia, fatigue, malaise — very frequent. HP:0001824 (Weight loss).

Skin (≈80%, often the presenting feature) - Neutrophilic dermatosis / Sweet-syndrome–like lesions — dominant pattern. HPO: HP:0200035 (Neutrophilic dermatosis) / HP:0000962 (Hyperkeratosis – not apt); best: HP:0200035. - Cutaneous vasculitis, leukocytoclastic vasculitis — HP:0011008 / HP:0025476 (Cutaneous small vessel vasculitis). - Skin biopsy classically shows a leukocytoclastic and neutrophilic/histiocytoid infiltrate with myeloid precursors carrying the UBA1 mutation.

Cartilage / musculoskeletal - Relapsing chondritis (auricular and nasal) — 36–54%. HPO: HP:0002770 (Chondritis) / HP:0100786 (auricular). A large fraction of "relapsing polychondritis" in older men is actually VEXAS. - Inflammatory arthritis / polyarthralgia — 28–58%. HP:0001369 (Arthritis).

Eye (30–46%) - Periorbital edema, scleritis, episcleritis, uveitis, orbital inflammation — HPO: HP:0100534 (Scleritis), HP:0000554 (Uveitis), HP:0100539 (Periorbital edema).

Lung (35–55%) - Pulmonary infiltrates, organizing pneumonia, pleural effusions, neutrophilic alveolitis — HPO: HP:0006530 (Abnormal pulmonary interstitial morphology) / HP:0002113 (Pulmonary infiltrates) / HP:0002202 (Pleural effusion).

Vascular / thrombotic (23–41%) - Venous thromboembolism (DVT/PE) predominant; some arterial. HPO: HP:0002625 (Deep venous thrombosis), HP:0002204 (Pulmonary embolism), HP:0001907 (Thromboembolism). Episodic/recurrent.

Hematologic (near-universal) - Macrocytic anemia — ~97%. HPO: HP:0001972 (Macrocytic anemia) / HP:0001903 (Anemia). Progressive, transfusion-dependent in many. - Cytoplasmic vacuoles in myeloid and erythroid precursors (bone marrow) — the pathognomonic morphologic clue. HPO: closest is HP:0011273 (Abnormal myeloid cell morphology) — (no precise "vacuolated precursor" HP term; data gap). - Thrombocytopenia — 10–48%. HP:0001873. - Myelodysplastic syndrome (MDS) — 31–53% (mostly low/very-low risk). HP:0002863 (Myelodysplasia). - Plasma-cell dyscrasia (MGUS / multiple myeloma) — 10–25%. HP:0012184 (Abnormal circulating immunoglobulin) / monoclonal gammopathy. - Markedly elevated CRP/ESR — near-universal. HP:0011227 (Elevated C-reactive protein level), HP:0003565 (Elevated erythrocyte sedimentation rate).

Other - Orchitis/epididymitis, aseptic meningitis, gastrointestinal inflammation, hearing loss reported less commonly.

Onset / severity / progression / QoL. Onset adult (median ~66 y). Course is chronic, relapsing-remitting with progressive cumulative organ damage; severity moderate-to-severe and frequently glucocorticoid-dependent. QoL impact is high: chronic high-dose steroid exposure, transfusion dependence, recurrent hospitalization, and substantial fatigue/pain burden. Formal EQ-5D/SF-36 data are sparse — (QoL instrument data gap).

4. Genetic / Molecular Information

Causal gene. UBA1 (ubiquitin-like modifier-activating enzyme 1; E1 enzyme). HGNC: HGNC:12469 (dismech CURIE form hgnc:12469); NCBI Gene 7317; Xp11.23; OMIM gene 314370. Encodes the sole or principal E1 that charges ubiquitin with ATP and hands it to E2 conjugating enzymes — the obligatory first step of essentially all cellular ubiquitylation.

Pathogenic variants (somatic, X-linked). - Canonical codon-41 variants (≈80–90% of cases): - p.Met41Thr — c.122T>C — most common; associated with more ocular inflammation; ~83% 5-yr survival. - p.Met41Val — c.121A>G — most aggressive; less chondritis, more undifferentiated systemic inflammation, worst survival (~60–77% 5-yr); lowest residual UBA1b. - p.Met41Leu — c.121A>C — frequent skin/Sweet phenotype; best survival (~100% 5-yr). - Splice and non-Met41 variants: e.g., c.118-1G>C, c.118-2A>C (splice-site), p.Ser56Phe, p.Gly477Ala, and others that also impair cytoplasmic UBA1b — these broaden the variant spectrum and are recognized in later cohorts (Poulter JA et al., Blood 2021, PMID:33690795; and subsequent series). (HUMAN_CLINICAL / IN_VITRO)

Classification. Pathogenic / likely pathogenic per functional + segregation-with-disease evidence; these are somatic mosaic calls, so ACMG germline rules apply imperfectly — interpretation hinges on variant allele fraction (VAF) and functional data.

Variant origin & allele fraction. Somatic, not germline. Restricted to the hematopoietic compartment (blood/marrow), absent in skin fibroblasts — a key diagnostic discriminator. VAF ranges ~4–95%, typically high in peripheral myeloid cells; the mutation enriches in myeloid lineage over time.

Population frequency. Not present in germline population databases (gnomAD) as a constitutional variant — it is an acquired somatic event, so "allele frequency" is age- and tissue-dependent rather than a fixed population number.

Functional consequence. Loss of cytoplasmic UBA1b → global reduction in cytoplasmic ubiquitylation (a partial loss-of-function with downstream gain-of-inflammatory-function at the cellular level). Met41 is the AUG start for the catalytically active cytoplasmic isoform; its loss forces use of a downstream Met67 start producing the dysfunctional UBA1c.

"Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis... patients with p.Met41Val have... lower residual translation of the normal cytoplasmic UBA1 isoform UBA1b." — Ferrada/Beck et al., Blood 2022 (PMID:35793465). (IN_VITRO + HUMAN_CLINICAL)

Modifier genes. Co-occurring clonal mutations — DNMT3A, TET2 (clonal hematopoiesis), and MDS-associated genes — modify hematologic trajectory and malignant risk.

Epigenetics. No primary epigenetic cause; however, the therapeutic efficacy of hypomethylating agents (azacitidine) implies DNA-methylation–sensitive clonal biology. Direct methylome studies are limited — (data gap).

Chromosomal abnormalities. Acquired monosomy X / loss of wild-type X is an important mechanism enabling disease in females and can accompany clonal evolution in males.

5. Environmental Information

• Environmental/toxic factors: None established as causal. (Data gap.)
• Lifestyle factors: No proven dietary/smoking/alcohol contribution to onset; smoking and cardiovascular risk factors are relevant only to thrombotic-complication management.
• Infectious agents: No infectious cause. Infections are a leading cause of death in VEXAS (immunosuppression + cytopenias), and intercurrent infection can trigger flares — but VEXAS is not an infectious disease. NCBI Taxonomy: not applicable.

The "environmental" driver is essentially endogenous somatic mutagenesis in aging hematopoiesis.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream):

1. Somatic UBA1 p.Met41 mutation in an HSPC → loss of cytoplasmic UBA1b → global reduction in cytoplasmic ubiquitylation. (initiating lesion; IN_VITRO + HUMAN_CLINICAL, PMID:33108101, PMID:35793465)
2. Impaired ubiquitin–proteasome protein quality control → ER stress and activation of the unfolded protein response (UPR) and dysregulated autophagy in mutant myeloid cells.
3. Innate immune activation: mutant monocytes/myeloid cells show inflammasome activation, NF-κB and type I/II interferon signatures, and elevated IL-6, IL-1β, TNF-α. Defective Lys63/Met1 (linear) polyubiquitylation of inflammatory signaling complexes dysregulates death/inflammation checkpoints.

"Mutant cells showed decreased ubiquitylation [activating] cellular stress responses that lead to upregulation of the unfolded-protein response... and a shared gene expression signature consistent with the activation of multiple innate immune pathways." — Beck DB et al., NEJM 2020 (PMID:33108101). (IN_VITRO)

1. Myeloid bias and dysplastic hematopoiesis: UBA1-mutant clones outcompete in the myeloid lineage; recent work shows inflammation and myeloid bias can arise via partly independent mechanisms downstream of UBA1 loss (Nature 2025, s41586-025-09815-0). The cytoplasmic vacuoles in marrow precursors are a morphologic readout of this proteostatic/autophagic stress.
2. Aberrant regulated cell death: Uba1-mutant macrophages undergo RIPK1/RIPK3-linked inflammatory cell death, amplifying sterile inflammation (biorxiv 2025; mechanistic literature). (MODEL_ORGANISM / IN_VITRO)
3. Clinical output: chronic, relapsing multi-organ neutrophilic/cytokine-driven inflammation plus progressive bone-marrow failure and clonal evolution to MDS/plasma-cell disease.

Molecular pathways / GO suggestions: - GO:0016567 protein ubiquitination (DECREASED) — the core lesion - GO:0000209 protein polyubiquitination - GO:0030968 endoplasmic reticulum unfolded protein response (INCREASED) - GO:0006914 autophagy (dysregulated) - GO:0032606 type I interferon production / GO:0034340 response to type I interferon (INCREASED) - GO:0070423 nucleotide-binding oligomerization domain containing signaling / GO:0140447 cytokine precursor processing (inflammasome) (INCREASED) - GO:0043123 positive regulation of canonical NF-κB signaling (INCREASED) - GO:0097190 apoptotic signaling / RIPK1-dependent necroptosis (INCREASED)

Cell types (CL suggestions): - CL:0000576 monocyte (key dysregulated effector) - CL:0000775 neutrophil (neutrophilic dermatosis, alveolitis) - CL:0000037 hematopoietic stem cell (clonal origin) - CL:0000839 myeloid lineage restricted progenitor cell - CL:0000764 erythroid lineage cell (vacuolated precursors) / CL:0000557 granulocyte monocyte progenitor cell - CL:0000786 plasma cell (associated dyscrasia)

Subcellular (GO cellular component): GO:0005783 endoplasmic reticulum; GO:0005829 cytosol (site of lost UBA1b activity); GO:0000502 proteasome complex.

Immune involvement: Prototypic autoinflammatory (innate-driven) disease, not classic autoimmunity — though autoantibody/overlap features occur. Cytokine drivers: IL-6, IL-1β, TNF-α, type I/II IFN.

Molecular profiling: Transcriptomics of patient marrow/blood shows interferon + inflammatory signatures arising early in primitive HSPCs and the myeloid lineage (Cell Reports Med / iScience 2023; PMC12092610, S2666379123003130). Single-cell genotype–phenotype mapping links the mutant clone directly to the inflammatory program and suggests therapeutic vulnerabilities (biorxiv 2024.05.19.594376). (IN_VITRO / COMPUTATIONAL)

7. Anatomical Structures Affected

Primary site: Bone marrow / hematopoietic system — the origin and engine. UBERON: UBERON:0002371 (bone marrow), UBERON:0000178 (blood).

Multi-organ secondary involvement (UBERON): - Skin — UBERON:0002097 (skin of body) / UBERON:0000014 (zone of skin) - Cartilage — auricular UBERON:0001691 (external ear) / nasal cartilage UBERON:0001737 (laryngeal cartilage—approx.); cartilage tissue UBERON:0002418 - Eye — UBERON:0000970 (eye); sclera UBERON:0001773; orbit UBERON:0001697 - Lung — UBERON:0002048 (lung); pleura UBERON:0000175 - Blood vessels (veins) — UBERON:0001638 (vein); vasculature UBERON:0002049 - Joints — UBERON:0000465 (material anatomical entity—joint) / UBERON:0001485 (synovial joint approx.)

Body systems: hematopoietic/immune, integumentary, respiratory, cardiovascular (venous), musculoskeletal, ocular/visual, occasionally nervous (aseptic meningitis) and reproductive (orchitis).

Tissue/cell level: myeloid and erythroid bone-marrow precursors (vacuolated); circulating monocytes and neutrophils; dermal neutrophilic/histiocytoid infiltrates; cartilage perichondrial inflammation.

Subcellular: ER (UPR), cytosol (ubiquitylation failure), proteasome; characteristic cytoplasmic vacuoles.

Localization/laterality: Generally systemic and bilateral (e.g., bilateral auricular chondritis, periorbital edema), though skin and pulmonary lesions can be patchy/asymmetric.

8. Temporal Development

• Onset: Adult/late-onset. Median ~66 y (IQR ~63–73); essentially never pediatric (somatic clonal acquisition with age). HPO onset: HP:0003581 (Adult onset) → HP:0003596 (Middle age onset)/late onset. Pattern usually insidious/subacute with episodic flares.
• Progression / stages: No formal staging. Conceptually: (1) early relapsing inflammatory phase often misdiagnosed as a rheumatologic syndrome → (2) glucocorticoid-dependent chronic inflammation with emerging cytopenias → (3) progressive marrow failure / transfusion dependence and clonal evolution (MDS, plasma-cell disease) → (4) end-stage cytopenias, infection, or transformation.
• Course: Chronic, relapsing-remitting with cumulative organ damage; lifelong. Spontaneous durable remission is rare; remissions are typically treatment-induced (steroids, JAK inhibitors, hypomethylating agents) or curative only via allogeneic transplant.
• Critical window: Earlier molecular diagnosis (recognizing VEXAS behind "relapsing polychondritis / Sweet / MDS in an older man") opens the window for clone-directed therapy and transplant evaluation before irreversible marrow failure.

9. Inheritance and Population

Epidemiology. - Prevalence (landmark genome-first study, Geisinger MyCode, 163,096 unselected adults): ~1 in 4,269 men >50 y and ~1 in 26,238 women >50 y; ~1 in 13,591 unrelated individuals >50 y overall.

"...estimated prevalence of disease-associated UBA1 variants... 1 in 4269 men and 1 in 26,238 women older than 50 years." — Beck DB et al., JAMA 2023;329(4):318-324 (PMID:36692560). (HUMAN_CLINICAL)

• This reframed VEXAS from "ultra-rare" to a relatively common cause of unexplained adult inflammation in older men, almost certainly under-diagnosed. Incidence figures are not yet firmly established — (data gap).

Genetics of transmission. - Inheritance pattern: Not inherited — somatic/acquired. Functionally X-linked in the sense that the male single-X dosage explains the strong sex skew, but there is no germline transmission to offspring and no recurrence risk in families. - Penetrance: Among carriers identified genome-first, penetrance of the combined inflammatory+hematologic phenotype was reported as high (approaching ~100% in symptomatic ascertainment), though milder/oligosymptomatic carriers are increasingly recognized. - Expressivity: Highly variable (chondritis-predominant vs skin-predominant vs MDS-predominant), partly by genotype. - Anticipation / germline mosaicism / founder effects / consanguinity / carrier frequency: Not applicable (somatic disease).

Demographics. - Sex ratio: Strongly male; ~96% male / ~4% female (females usually require monosomy X or skewed XCI). - Age distribution: Overwhelmingly >50 y; peak 6th–8th decades. - Ethnic/geographic distribution: Reported worldwide across ancestries; no strong ethnic predilection established (the major cohorts are US and European). No endemic geography (not environmental/infectious).

10. Diagnostics

Definitive test — molecular. - UBA1 somatic mutation detection in peripheral blood and/or bone marrow (myeloid-enriched fractions increase sensitivity). Methods: targeted Sanger (high-VAF), NGS panels, ddPCR, or WGS/WES (caution: high-VAF somatic UBA1 can be misread as hemizygous germline on exome — PMID:36038944). Confirm somatic status by absence in skin fibroblasts/non-hematopoietic tissue.

Morphologic clue. - Bone marrow aspirate: cytoplasmic vacuoles in myeloid and erythroid precursor cells — the original "V." Highly suggestive but not 100% specific/sensitive.

Laboratory. - Persistently elevated CRP/ESR; macrocytic anemia (high MCV), variable thrombocytopenia/leukopenia/monocytopenia; ferritin often high. LOINC: CRP (LOINC:1988-5), ESR (LOINC:4537-7), MCV (LOINC:787-2), Hemoglobin (LOINC:718-7). - SPEP/immunofixation for monoclonal protein (plasma-cell dyscrasia screen).

Imaging. CT chest for pulmonary infiltrates/effusions; vascular imaging for VTE; cross-sectional imaging for large-vessel vasculitis when GCA/large-vessel overlap suspected.

Histopathology. Skin/marrow biopsy: neutrophilic/leukocytoclastic infiltrates, perichondrial inflammation; marrow shows myeloid hyperplasia ± dysplasia and vacuolated precursors.

Diagnostic criteria. No validated formal criteria yet. Working approach (GeneReviews; Koster/Mayo and others): adult male with relapsing multisystem inflammation (chondritis/skin/eye/lung) + macrocytic anemia/cytopenias ± marrow vacuoles + steroid dependence → test UBA1. Proposed clinical screening scores exist (e.g., to prioritize who to sequence) but are not consensus-finalized — (data gap / evolving).

Differential diagnosis (to distinguish): relapsing polychondritis, Sweet syndrome, polyarteritis nodosa, giant cell arteritis/large-vessel vasculitis, adult-onset Still disease, MDS without autoinflammation, IgG4-related disease, Behçet disease. The unifying discriminator is the somatic UBA1 mutation + marrow vacuoles + macrocytic anemia in an older man.

Screening. No population newborn/carrier screening (somatic disease). Emerging concept: opportunistic UBA1 testing in older men presenting with otherwise-unexplained relapsing inflammation plus macrocytosis.

11. Outcome / Prognosis

• Mortality / survival: High. Estimated 5-year mortality up to ~50% from symptom onset in early cohorts; the discovery cohort reported 10/25 deaths.

"Of the 25 patients, 10 died during the study period." — Beck DB et al., NEJM 2020 (PMID:33108101). (HUMAN_CLINICAL)

• Genotype-stratified 5-yr survival: p.Met41Leu ~100% > p.Met41Thr ~83% > p.Met41Val ~60–77% (Ferrada/Beck, Blood 2022, PMID:35793465).
• Disease-specific mortality drivers: progressive cytopenias/marrow failure, infection (compounded by immunosuppression), thromboembolism, transformation to MDS/AML or progressive plasma-cell disease.
• Prognostic factors: p.Met41Val genotype and transfusion dependence predict worse survival; ear chondritis associates with better prognosis; co-mutations in myeloid-malignancy genes worsen outcome; age and comorbidity matter.
• Morbidity: Substantial — chronic steroid toxicity (osteoporosis, diabetes, infection), transfusion dependence, recurrent thrombosis, cumulative organ damage. Most patients fail to achieve durable drug-free remission.
• Recovery potential: No spontaneous cure; allogeneic HSCT is the only potentially curative option and can eradicate the mutant clone, at the cost of significant transplant-related morbidity/mortality.

12. Treatment

No regulatory-approved therapy and no consensus guideline exist; management is empirical, drawn from cohorts/case series. Two strategic arms: (A) suppress inflammation and (B) target/eradicate the UBA1-mutant clone.

A. Anti-inflammatory / immunosuppressive - Glucocorticoids — first-line, almost universally effective but disease is steroid-dependent; chronic toxicity drives the need for steroid-sparing agents. MAXO: MAXO:0000058 (pharmacotherapy) / corticosteroid; CHEBI:50858 (corticosteroid) / CHEBI:8378 (prednisone). - JAK inhibitors — ruxolitinib is the most effective JAK inhibitor (superior to tofacitinib/baricitinib/upadacitinib), with meaningful clinical response in roughly half of treated patients.

"Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome." — Heiblig M et al., Blood 2022 (PMID:35609174). (HUMAN_CLINICAL) CHEBI:75045 (ruxolitinib); modality SMALL_MOLECULE; target JAK1/JAK2. - IL-6 inhibition (tocilizumab) — partial benefit (~26% response). CHEBI/NCIT tocilizumab; modality MONOCLONAL_ANTIBODY. - IL-1 inhibition (anakinra, canakinumab) — limited efficacy (<10%); anakinra can cause severe injection-site reactions in VEXAS. - Conventional DMARDs (methotrexate, azathioprine), TNF inhibitors — generally poorly/inconsistently effective.

B. Clone-directed (hematologic) - Hypomethylating agents — azacitidine — clinical responses (~5/11 with concurrent MDS in GeneReviews summary) and, importantly, occasional deep/complete molecular remission of the UBA1 clone, sometimes permitting therapy de-escalation.

"Two patients achieved complete molecular remission of the underlying UBA1 mutant clone... receiving treatment with the hypomethylating agent azacitidine." — Blood / Annals of Hematology 2023–2025 reports. (HUMAN_CLINICAL) CHEBI:2038 (azacitidine); MAXO chemotherapy/pharmacotherapy. - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) — the only curative therapy; eradicates the mutant clone. Systematic review/meta-analysis supports efficacy in selected, fit patients, balanced against transplant-related mortality (Nature BMT 2024, s41409-024-02375-3). MAXO: MAXO:0001175/MAXO:0010039 (hematopoietic/organ transplantation); modality CELL_THERAPY.

Emerging / experimental. UBA1-targeted and clone-selective strategies, optimized HMA + JAKi combinations, and refined transplant conditioning are under active study. Recent retrospective treatment-outcome cohorts (Lancet Rheumatology 2025, PIIS2665-9913(25)00034-7) are defining comparative effectiveness. Relevant trial registries: search ClinicalTrials.gov for "VEXAS" (e.g., natural-history/genetics protocol NCT06004349; several interventional JAKi/HMA studies). (Add specific NCT IDs at curation time.)

Supportive care. Transfusion support, infection prophylaxis (especially under steroids/JAKi/HMA — PJP prophylaxis), anticoagulation for VTE, bone protection, vaccination. MAXO:0000950 (supportive care).

Pharmacogenomics. No VEXAS-specific PGx; standard JAKi/azacitidine considerations apply.

13. Prevention

• Primary prevention: None possible — disease arises from a random somatic mutation in aging hematopoiesis; no modifiable exposure, no vaccine.
• Secondary prevention (early detection): The highest-yield "prevention" is earlier diagnosis — testing UBA1 in older men with unexplained relapsing inflammation + macrocytic anemia to intervene before marrow failure. Genome-first ascertainment (PMID:36692560) shows latent/under-recognized cases exist.
• Tertiary prevention (complications): VTE prophylaxis/anticoagulation, infection prophylaxis during immunosuppression, steroid-toxicity mitigation (bone, glucose), transfusion-iron management, and timely transplant referral to prevent clonal progression.
• Genetic counseling: Reassurance that VEXAS is somatic and not heritable — no offspring/sibling recurrence risk, no prenatal/carrier testing indicated. This is an important counseling point distinguishing it from germline autoinflammatory syndromes.
• Public-health/environmental interventions: Not applicable.

14. Other Species / Natural Disease

• Taxonomy: Human disease (NCBITaxon:9606). No naturally occurring animal counterpart described.
• Orthologous gene: Uba1 is highly conserved — mouse Uba1 (NCBI Gene 22201), zebrafish uba1. Strong evolutionary conservation of the ubiquitin-activation step makes the mechanism studyable across species.
• Natural disease in animals (OMIA/veterinary): None reported — (data gap / not applicable). There is no spontaneous companion-animal or wildlife VEXAS analog on record.
• Comparative biology: The disease itself is human-specific (requires the human UBA1b cytoplasmic-isoform start-codon architecture at Met41 plus age-related clonal hematopoiesis); engineered animal models (below) are the route to cross-species mechanistic study.
• Transmission/zoonosis: Not applicable (non-communicable, somatic).

15. Model Organisms

• Zebrafish (Danio rerio): uba1-perturbation models recapitulate IRF3 accumulation, excessive type I interferon, and inflammation, supporting the proximal-ubiquitylation→IFN mechanism. (MODEL_ORGANISM) — useful for innate-immune readouts and drug screening. ZFIN resource.
• Mouse (Mus musculus): Conditional/hematopoietic Uba1-mutant or knockdown models show UPR activation and myeloid bias, with recent work dissecting inflammation vs myeloid-bias as partly independent of RIPK3–CASP8 (Nature 2025, s41586-025-09815-0). (MODEL_ORGANISM) MGI resource; IMPC for Uba1 alleles.
• In vitro / cellular: Patient-derived monocytes/macrophages and CD34+ HSPCs, iPSC-derived myeloid cells, and engineered Met41-mutant cell lines reproduce reduced ubiquitylation, ER/UPR stress, inflammasome activation, and RIPK1-mediated death. (IN_VITRO) — workhorse systems for mechanism and therapeutic-vulnerability screens (single-cell genotype–phenotype mapping, biorxiv 2024.05.19.594376).
• Phenotype recapitulation: Models reproduce the molecular/inflammatory arms well (ubiquitylation defect, UPR, IFN/inflammasome, myeloid skewing).
• Limitations: No single model fully reproduces the multi-organ relapsing clinical syndrome (chondritis, skin, vacuolated precursors, MDS evolution) seen in patients; the age-dependent somatic-clonal acquisition and the human-specific UBA1b isoform context are hard to mimic. Treat model→human translation as a HUMAN_MODEL_MISMATCH candidate where mouse/zebrafish data inform mechanism but human-disease fidelity remains open.
• Resources: MGI, IMPC, ZFIN, Cellosaurus (patient/iPSC lines), GEO (patient transcriptomics).

Key Citations (PMID-anchored)

Sources (web): - Beck et al. NEJM 2020 — PMID:33108101 - Beck et al. JAMA 2023 — PMID:36692560 - GeneReviews: VEXAS Syndrome — NBK614471 - OMIM #301054 - Ferrada/Beck Blood 2022 — Translation of cytoplasmic UBA1 (PMC9523373) - Heiblig et al. Blood 2022 — Ruxolitinib (PMID:35609174) - Nature 2025 — Independent mechanisms of inflammation and myeloid bias - NCI/DCEG genome-first prevalence summary - Bone Marrow Transplantation 2024 — allo-HSCT meta-analysis - Lancet Rheumatology 2025 — treatment outcomes cohort

Curation notes for the dismech entry (kb/disorders/VEXAS_Syndrome.yaml)

• Category: Complex — clean fit; this is a clonal-hematopoietic autoinflammatory disorder bridging rheumatology and hematology.
• MONDO: MONDO:0026777 · Gene: hgnc:12469 (UBA1) · note somatic origin in the genetic block (GENO somatic mutation, not germline inheritance).
• Pathophysiology causal chain to encode: UBA1b loss → ↓cytoplasmic ubiquitylation (GO:0016567 DECREASED) → ER/UPR stress (GO:0030968 INCREASED) → inflammasome/NF-κB/type-I-IFN (GO:0034340, GO:0043123 INCREASED) → myeloid-biased dysplastic hematopoiesis + multi-organ neutrophilic inflammation.
• Module conformance candidates: This is a natural fit for an autoinflammation / innate-immune-dysregulation pattern; if a "clonal hematopoiesis" or "type-I-interferonopathy"-adjacent module exists or is created, link it. (No exact existing module from the CLAUDE.md list maps cleanly — flag as a possible new-module opportunity rather than forcing a fit.)
• Before committing evidence: every PMID above must be just fetch-reference'd and every snippet: verified as an exact substring of the real abstract (the quotes here are paraphrase-adjacent search excerpts and must be replaced with verified verbatim text). Run just validate, just validate-references, and just validate-terms-file on the file.
• Data gaps flagged: ICD-11 code; precise incidence; QoL instrument data; epigenome studies; animal natural-disease (OMIA); finalized formal diagnostic criteria. Consider discussions with kind: KNOWLEDGE_GAP for these, and kind: HUMAN_MODEL_MISMATCH for the model-organism translational gap.